Published in Cancer Weekly, July 21st, 1997
Troponin I is an anti-angiogenic product in preclinical development. The company said that in a recently concluded experiment, where human breast cancer was implanted into nude mice and recombinant Troponin I was then administered subcutaneously over a 28-day period, tumor growth in the treated animals was significantly inhibited compared to tumor growth in the control mice.
"The results of this study, together with our previously reported results showing inhibition of human...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.